Dianthus Therapeutics to Participate in Three Investor Conferences During September
Dianthus Therapeutics (Nasdaq: DNTH) announced participation in three September 2026 investor conferences.
Rhea-AI Summary
Dianthus Therapeutics (Nasdaq: DNTH) announced participation in three September 2026 investor conferences. At the Wells Fargo 21st Annual Healthcare Conference on September 8, executives will hold one-on-one meetings. CEO Marino Garcia will join fireside chats at Citi's Biopharma Back to School Conference on September 9 and the Cantor Global Healthcare Conference on September 10, alongside additional one-on-one investor meetings. Webcasts of the Citi and Cantor presentations will be available through the Investors section of the Dianthus Therapeutics website.
Positive
- None.
Negative
- None.
News Market Reaction – DNTH
In the Sep 1 session, DNTH gained 0.96%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 10 | Board appointment proposal | Neutral | -3.0% | Agomab proposed appointing Dianthus CEO Marino Garcia to its board. |
| Aug 04 | Q2 earnings report | Positive | +1.9% | Dianthus reported Q2 results and clinical progress across neuromuscular programs. |
| Aug 04 | Pipeline announcement | Positive | +4.1% | Dianthus announced DNTH312, a bifunctional fusion protein candidate for autoimmune diseases. |
| Aug 03 | Inducement grants | Neutral | +4.1% | Dianthus granted options covering 87,000 shares to six newly hired employees. |
| Jul 02 | Inducement grants | Neutral | -1.1% | Dianthus granted options covering 58,000 shares to five newly hired employees. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent DNTH news reactions were mixed, including 1.9% and 4.13% gains on August 4 announcements and a -1.06% reaction to July inducement grants.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in three investor conferences.
- Wells Fargo 21st Annual Healthcare Conference: Marino Garcia, CEO, and Ryan Savitz, EVP, CFO & CBO of Dianthus Therapeutics, will host one-on-one investor meetings on September 8, 2026.
- Citi's 2026 Biopharma Back to School Conference: Marino Garcia will participate in a fireside chat on Wednesday, September 9, 2026, at 4:20 p.m. ET and host one-on-one investor meetings.
- 2026 Cantor Global Healthcare Conference: Marino Garcia will participate in a fireside chat on Thursday, September 10, 2026, at 8:35 a.m. ET and host one-on-one investor meetings.
Webcasts of the presentations at the Citi and Cantor conferences may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
